secwatch.observer — SEC 8-K summary
======================================

Issuer:     Protagonist Therapeutics, Inc (PTGX)
CIK:        0001377121
Form:       8-K
Filed at:   2025-02-21T23:59:59+00:00
Accession:  0001104659-25-015897
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Protagonist reports Q4 net income $131.7M; cash $559.2M; upcoming Phase 3 readouts in March 2025
--------------------------------------------------------------------------------

- Net income of $131.7M in Q4 2024 ($2.11 basic EPS) vs $27.3M in Q4 2023; FY 2024 net income $275.2M vs net loss of $79.0M in FY 2023.
- License & collaboration revenue of $434.4M for FY 2024, up from $60.0M in FY 2023, including $165M milestone from JNJ.
- Cash, equivalents, and marketable securities $559.2M at Dec 31, 2024; plus $165M milestone received Jan 2025; runway through at least end of 2028.
- Topline results for rusfertide Phase 3 VERIFY (polycythemia vera) and icotrokinra Phase 2b ANTHEM (ulcerative colitis) expected in March 2025.
- Nominated PN-881, an oral IL-17 receptor antagonist; plans to nominate oral obesity candidate in Q2 2025 and oral hepcidin candidate in Q4 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1377121/000110465925015897/0001104659-25-015897-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1377121/000110465925015897/tm257151d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-015897

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer